Lino Biotech offers the MACS® Matchmaker platform, a focal molography‑based system that provides label‑free kinetic binding measurements directly in complex matrices such as serum, lysate, or crude supernatant. Its 8‑plex chip enables up to 64 simultaneous interactions with high sensitivity and low background, allowing biotech and pharma R&D teams to rank antibody, Fc‑engineered, PROTAC, and biosimilar candidates from discovery through lot release without assay redevelopment.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional kinetic binding assays such as SPR require purified samples, suffer from high background noise, and are limited to single‑pair measurements, leading to long turnaround times and unreliable data when testing in complex matrices like serum or cell lysate.
Solution
The MACS® Matchmaker platform replaces these conventional methods with focal molography, a label‑free optical technique that detects only the coherent mass density of specifically bound analytes. By measuring directly in serum, lysate, or crude supernatant, the system eliminates the need for pre‑purification and avoids matrix‑induced background. An 8‑plex chip holds eight pre‑conjugated ligands, each replicated four times, enabling up to 64 simultaneous interactions in a single injection series. The approach delivers clean kinetic data with sub‑two‑fold resolution, allowing reliable ranking of candidates from early discovery through lot release without redeveloping assays. This multiplexed, matrix‑compatible workflow accelerates decision‑making and reduces experimental bottlenecks across antibody, Fc‑receptor, PROTAC, and biosimilar projects.
Target Audience
Primary customers are biotech and pharmaceutical R&D teams developing antibodies, Fc‑engineered therapeutics, PROTACs, and biosimilars who need high‑throughput, matrix‑compatible kinetic profiling.
Features
- Focal molography measures coherent mass density, rendering non‑specific binding and matrix noise invisible
- 8‑plex chip format with eight ligands, each in four replicates, providing mean values and confidence intervals from one run
- Capability to run up to 64 parallel binding interactions in a single injection series
- Direct kinetic measurements in crude samples (serum, lysate, cell supernatant) without purification or method redevelopment
- High sensitivity that resolves sub‑twofold differences, enabling precise candidate ranking
- Consistent workflow from early discovery to quality‑control and biosimilar comparability on the same instrument